Kinnate Biopharma’s Strategic Merger with XOMA for Cancer Innovation
Company Announcements

Kinnate Biopharma’s Strategic Merger with XOMA for Cancer Innovation

Kinnate Biopharma (KNTE) has released an update.

Kinnate Biopharma Inc. has entered into a Merger Agreement with XOMA Corporation which will see XOMA acquiring all outstanding shares of Kinnate at a set base price plus additional cash and contingent value rights. The independent board committee of Kinnate unanimously approved the transaction as beneficial for shareholders, recommending they accept the offer. The merger is not subject to a financing condition and includes certain termination rights and a potential termination fee. This strategic move aims to accelerate development in cancer treatment, with XOMA eager to leverage Kinnate’s innovative product candidates, including pan-RAF inhibitors for various tumors.

For further insights into KNTE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskKinnate Biopharma’s Strategic Shift and Corporate Evolution
TheFlyXoma announces closing of tender offer
Catie PowersKNTE Earnings this Week: How Will it Perform?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App